Adam Boehler officially named new CMMI director

In an email to CMS staff, agency administrator Seema Verma announced Adam Boehler, CEO of home-based care startup Landmark Health, has been named the new head of the Center for Medicaid and Medicare Innovation (CMMI).

Boehler’s selection has been rumored for months. He doesn’t bring any government experience, with his resume mostly centered on venture capital and startups. Before founding Landmark Health, he was running another healthcare startup, lab management company Accumen. Other past roles include executive vice president and general manager at analytics provider MedeFinance and a principal healthcare investor at Accretive.

“Adam is widely regarded as an innovative leader in the private sector and in him we are lucky to have someone who has designed and implemented new, patient-focused approaches to healthcare delivery,” Verma wrote to CMS staff.

How exactly Trump administration officials will utilize CMMI remains an open question. Created under the Obama administration, the center was the driving force behind sometimes-controversial experiments with Medicaid and Medicare payment models. Some of those plans were rolled back under Verma and former HHS Secretary Tom Price, like their cancellation of several mandatory bundled payment models for cardiac and orthopedic care.

Since then, CMS has collected comments on a “new direction” for CMMI, with the promise the center would focus on mandatory models in the future. The second HHS Secretary under President Donald Trump, Alex Azar, has a different opinion on mandatory payment experiments, saying in one of his confirmation hearings he would support them if it was necessary to “get adequate data.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.